What is the best oral antibiotic for an uncomplicated bacterial infection of the buttock (e.g., cellulitis or small abscess)?

Best Oral Antibiotic for Buttock Infection

For an uncomplicated bacterial infection of the buttock, the best oral antibiotic depends on whether the infection is purulent (with drainage/abscess) or nonpurulent (simple cellulitis without pus).

Treatment Algorithm

Step 1: Classify the Infection Type

Purulent infection (abscess, furuncle, or cellulitis with purulent drainage):

• First-line choice: Trimethoprim-sulfamethoxazole (TMP-SMX) 1
• Alternative: Doxycycline or clindamycin 1
• Duration: 5-10 days 1

The buttock is a common site for CA-MRSA abscesses, and empirical coverage for MRSA is recommended for purulent infections 1. TMP-SMX has 95-100% susceptibility against CA-MRSA strains 1 and demonstrated superior treatment success (91%) compared to cephalexin (74%) in MRSA-prevalent areas 2. If an abscess is present, incision and drainage is the primary treatment 1, 3, 1, with antibiotics added for extensive disease, systemic symptoms, or failure to respond to drainage alone 1, 3.

Nonpurulent infection (simple cellulitis without drainage or abscess):

• First-line choice: Cephalexin or amoxicillin 1
• These β-lactams target β-hemolytic streptococci, the primary pathogen 1
• Duration: 5-10 days 1

Step 2: Assess for MRSA Risk Factors

Add MRSA coverage (switch to TMP-SMX, doxycycline, or clindamycin) if nonpurulent cellulitis occurs with:

• Penetrating trauma
• Injection drug use
• Known MRSA colonization
• Failure to respond to β-lactam therapy within 48-72 hours
• Signs of systemic illness 1

Step 3: Consider Dual Coverage Scenarios

If both streptococcal and MRSA coverage is needed:

• Clindamycin alone (covers both) 1, OR
• TMP-SMX or doxycycline PLUS amoxicillin 1

Clindamycin monotherapy is convenient but carries higher risk of diarrhea (OR 2.71) compared to TMP-SMX 4. Check local clindamycin resistance rates—use only if <10% resistance 1.

Key Evidence Strengths

The IDSA guidelines 1 provide the strongest framework (A-I to A-II evidence), consistently recommending TMP-SMX for purulent SSTI and β-lactams for nonpurulent cellulitis. Research evidence supports this: TMP-SMX showed significantly better outcomes than cephalexin in MRSA-prevalent settings 2, and a network meta-analysis confirmed TMP-SMX and clindamycin reduce treatment failure, recurrence, and hospitalization for abscesses 4.

Critical Pitfalls to Avoid

1. Don't use cephalosporins for purulent infections in MRSA-prevalent areas—they showed no benefit over placebo for abscesses 4 and had 74% success vs. 91% for TMP-SMX 2

2. Don't automatically cover MRSA for simple nonpurulent cellulitis—β-hemolytic streptococci remain the primary pathogen, and unnecessary MRSA coverage increases adverse effects without benefit 1, 5

3. Don't use rifampin as monotherapy or adjunctive therapy for SSTI 1, 3, 1

4. Avoid tetracyclines in children <8 years 1, 3

5. Avoid TMP-SMX in third-trimester pregnancy (category C/D) and infants <2 months 1

Special Considerations

• Obese patients and those with moderate-to-severe cellulitis: Clindamycin showed superior outcomes compared to cephalexin in these subgroups 2

• Elderly patients on ACE inhibitors/ARBs with renal insufficiency: Use TMP-SMX cautiously due to hyperkalemia risk 1

• Treatment failure: If no improvement within 48-72 hours on β-lactam, switch to MRSA-active agent 1